IDYA
Price
$27.16
Change
+$1.33 (+5.15%)
Updated
Sep 5 closing price
Capitalization
2.38B
66 days until earnings call
MRUS
Price
$67.47
Change
+$1.24 (+1.87%)
Updated
Sep 5 closing price
Capitalization
5.1B
54 days until earnings call
Interact to see
Advertisement

IDYA vs MRUS

Header iconIDYA vs MRUS Comparison
Open Charts IDYA vs MRUSBanner chart's image
IDEAYA Biosciences
Price$27.16
Change+$1.33 (+5.15%)
Volume$1.65M
Capitalization2.38B
Merus
Price$67.47
Change+$1.24 (+1.87%)
Volume$635.52K
Capitalization5.1B
IDYA vs MRUS Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. MRUS commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Buy and MRUS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (IDYA: $27.16 vs. MRUS: $67.47)
Brand notoriety: IDYA and MRUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 163% vs. MRUS: 100%
Market capitalization -- IDYA: $2.38B vs. MRUS: $5.1B
IDYA [@Biotechnology] is valued at $2.38B. MRUS’s [@Biotechnology] market capitalization is $5.1B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileMRUS’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • MRUS’s FA Score: 1 green, 4 red.
According to our system of comparison, MRUS is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 5 TA indicator(s) are bullish while MRUS’s TA Score has 3 bullish TA indicator(s).

  • IDYA’s TA Score: 5 bullish, 4 bearish.
  • MRUS’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than MRUS.

Price Growth

IDYA (@Biotechnology) experienced а +10.63% price change this week, while MRUS (@Biotechnology) price change was +2.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

IDYA is expected to report earnings on Nov 11, 2025.

MRUS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRUS($5.1B) has a higher market cap than IDYA($2.38B). MRUS YTD gains are higher at: 60.452 vs. IDYA (5.681). MRUS has higher annual earnings (EBITDA): -347.56M vs. IDYA (-380.2M). MRUS has more cash in the bank: 710M vs. IDYA (670M). MRUS has less debt than IDYA: MRUS (11M) vs IDYA (26.6M). MRUS has higher revenues than IDYA: MRUS (56.2M) vs IDYA (7M).
IDYAMRUSIDYA / MRUS
Capitalization2.38B5.1B47%
EBITDA-380.2M-347.56M109%
Gain YTD5.68160.4529%
P/E RatioN/AN/A-
Revenue7M56.2M12%
Total Cash670M710M94%
Total Debt26.6M11M242%
FUNDAMENTALS RATINGS
IDYA vs MRUS: Fundamental Ratings
IDYA
MRUS
OUTLOOK RATING
1..100
2011
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
54
Fair valued
PROFIT vs RISK RATING
1..100
6819
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
4744
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRUS's Valuation (54) in the Biotechnology industry is in the same range as IDYA (63) in the null industry. This means that MRUS’s stock grew similarly to IDYA’s over the last 12 months.

MRUS's Profit vs Risk Rating (19) in the Biotechnology industry is somewhat better than the same rating for IDYA (68) in the null industry. This means that MRUS’s stock grew somewhat faster than IDYA’s over the last 12 months.

IDYA's SMR Rating (97) in the null industry is in the same range as MRUS (98) in the Biotechnology industry. This means that IDYA’s stock grew similarly to MRUS’s over the last 12 months.

MRUS's Price Growth Rating (44) in the Biotechnology industry is in the same range as IDYA (47) in the null industry. This means that MRUS’s stock grew similarly to IDYA’s over the last 12 months.

MRUS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that MRUS’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAMRUS
RSI
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
68%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
80%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
75%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
Bearish Trend 9 days ago
77%
Bearish Trend 9 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
76%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
THGCX26.440.13
+0.49%
Thornburg International Equity C
GGHSX40.050.10
+0.25%
Invesco Health Care R6
RIDGX27.25N/A
N/A
American Funds Income Fund of Amer R6
GSRFX12.92N/A
N/A
Goldman Sachs Rising Dividend Gr R6
JACDX10.55N/A
N/A
JHancock Global Environmental Opps R6

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with SYRE. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+5.15%
SYRE - IDYA
61%
Loosely correlated
+0.06%
NRIX - IDYA
61%
Loosely correlated
+8.66%
CGON - IDYA
60%
Loosely correlated
+6.88%
IMNM - IDYA
59%
Loosely correlated
+7.35%
XENE - IDYA
58%
Loosely correlated
+1.48%
More

MRUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRUS has been loosely correlated with CGON. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if MRUS jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRUS
1D Price
Change %
MRUS100%
+1.87%
CGON - MRUS
52%
Loosely correlated
+6.88%
IDYA - MRUS
51%
Loosely correlated
+5.15%
RVMD - MRUS
49%
Loosely correlated
+3.98%
IMVT - MRUS
47%
Loosely correlated
+6.33%
ACLX - MRUS
46%
Loosely correlated
+0.64%
More